A

Abbott

Makes heart devices, glucose sensors and lab tests

Regional Sales Director - CRM

Full-Time
$130.6k - $240.8k
Expert
Bachelor's, Master's
Dallas, TX, USA+1 moreMore locations: Fort Worth, TX, USA
RemoteMust live in the region and may travel more than 50% depending on staffing and regional demands.
Sales & Account ManagementField Sales

About the job

Requirements
  • A Bachelor's degree in Business Administration, Marketing, or equivalent is required.
  • At least 8 years of progressively more responsible work experience in Tachycardia/Bradycardia product areas or a related discipline, including direct experience in CRM product sales preferred.
  • Proven and documented sales and clinical performance in the cardiology or cardiovascular field.
  • Ability to lead workstreams and initiatives using critical thinking skills.
  • Ability to direct and monitor direct reports' clinical and sales objectives, quality, outcomes, and sales performance measures.
  • Ability to perform the job in a quality system environment; inadequate performance can result in noncompliance with governmental regulations.
  • Ability to solve problems with a fact-based, solutions-oriented approach.
  • Must satisfy vendor credentialing requirements for hospital access, which may include COVID-19 vaccination; accommodations may be requested for medical or religious reasons.
Responsibilities
  • Direct CRM sales of Abbott products and services in the assigned region, including identifying and evaluating market opportunities and sales potential and establishing and achieving sales and clinical objectives.
  • Lead and coach territory managers and clinical specialists to develop a high-performing team for commercial and clinical trial responsibilities.
  • Meet authorization training requirements to support CRM procedures and provide competent clinical coaching to the team.
  • Support and achieve the regional sales plan.
  • Develop a safe learning environment and positive team culture.
  • Create a supportive work environment through weekly team calls, discovery workshops, regional meetings, and individual discussions.
  • Recruit, onboard, coach for sales and clinical performance, and develop direct reports.
  • Support diversity and team contributions toward organizational objectives and CRM franchise development; assist individuals with quarterly goals and development plans, and provide annual performance reviews.
  • Guide targeting and customer and account engagement planning to advance the commercial sales process.
  • Prepare regional sales forecasts, assess market potential, and prepare regional CRM sales expense estimates.
  • Provide accurate sales forecasts and drive sales accountability through forecasting.
  • Conduct quarterly field travel with the team to visit customers and ensure clinical competencies and sales advancement.
  • Propose strategies and initiatives to improve franchise customer focus and support.
  • Build cross-functional partnerships with marketing, training, enterprise accounts, and clinical trial teams to further franchise and organizational objectives.
  • Monitor compliance with company policies and procedures.
  • Assist with case support, proctor planning, and conflict resolution.
  • Oversee the annual regional budget and its compliance.
  • Approve direct reports' expense reports and address compliance issues as needed.
  • Complete vendor credentialing for hospital access as required.
  • Stay current on developments in the field, regulatory requirements, company products, markets and objectives, and industry trends.
  • Resolve or facilitate resolution of problems, identify causes, and prevent recurrence.
  • Mentor staff in developing solutions to complex problems that may significantly affect organizational budgets or commitments, and develop original solutions.
  • Assist with contract negotiation, customer engagement, performance management, and direct reports' clinical competency development.
  • Coach the team to proactively support CRM procedures for safe outcomes and drive continuing education in the region.
  • Set the regional sales strategy to meet franchise goals.
Desired Qualifications
  • A Master's degree is preferred.
  • Prior commercial and clinical trial experience in cardiology or cardiovascular fields.
  • Documented successful leadership experience with sales and clinical teams.
  • Abbott cardiovascular experience is a stronger consideration.
  • Direct experience in CRM product sales is preferred.

About the company

A

Abbott

View
Website

Abbott makes medical devices, diagnostic tests, nutrition products and branded generic drugs for hospitals, laboratories, pharmacies and patients. Its best-known product is the FreeStyle Libre, a coin-sized sensor worn on the upper arm that tracks blood sugar around the clock without routine finger pricks. Its other lines run from heart valves, pacemakers and brain stimulators to lab analyzers, rapid tests and mail-in colon cancer screening kits, and Abbott earns money by selling these products to health systems, labs, retailers and consumers. The company was founded in 1888 by Chicago physician Wallace Abbott and is based in Abbott Park, Illinois.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to Abbott

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Devices carry the growth: Abbott's device sales rose 8.4% on a comparable basis from April to June 2026.
  • Diabetes teams get a launch to build: FDA authorized Libre Duo, the first glucose and ketone sensor, in August 2026.
  • Abbott bought a cancer screening business: its roughly $21 billion Exact Sciences purchase closed in March 2026.

What critics are saying

  • Formula lawsuits linger: after a $670 million August 2026 settlement, about 1,700 suits over preemie formula remain.
  • Nutrition staff sit in a shrinking unit: Abbott's nutrition sales fell 3.6% comparably from April to June 2026.
  • Abbott's top product drew a severe recall: FDA flagged Libre 3 sensor errors linked to seven deaths in January 2026.

What makes Abbott unique

  • Abbott's drug arm skips the US: it sells branded generic medicines only in markets such as India and Latin America.
  • Abbott sells to grocery shoppers too: Similac formula and Ensure shakes sit on store shelves, unlike device rivals.
  • Abbott's heart implant reports to patients: CardioMEMS lets heart failure patients read their own artery pressure on phones.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Flexible Work Hours
  • Remote Work Options
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Professional Development Budget
  • Wellness Program

Growth & Insights and Company News

6 month growth

-6%

1 year growth

5%

2 year growth

5%
DrugDu
Oct 26th, 2026
Another global medical device giant has officially announced its spin-off!

Another global medical device giant has officially announced its spin-off! October 26, 2026 Source: drugdu 43 According to recent foreign media reports, Abbott announced the spin-off of its businesses and a downward revision of its full-year guidance after releasing its Q3 results. Abbott announced plans to spin off its nutrition business into an independent company by the end of 2027. The new independent company will have annual sales of $8.5 billion, 16,000 employees, and 14 manufacturing sites. Its product portfolio will include well-known brands such as Ensure (a nutritional supplement drink), PediaSure (a pediatric nutritional supplement), Glucerna (a diabetes management nutrition brand), and Similac (an infant formula brand). Daniel Salvadori, the current Executive Vice President and Group President of Mature Pharmaceuticals and Nutrition Products, will become the CEO of this independent company. The spin-off plan includes Abbott distributing shares of the independent nutrition company to Abbott shareholders. Upon completion of the spin-off, Abbott shareholders will hold shares in both Abbott and the independent nutrition company. It is worth mentioning that before the spin-off plan was announced, Abbott had already reached settlement agreements worth more than $1 billion in lawsuits related to its infant formula products - of which $670 million was used to settle 2,000 claims and nearly $385 million was used to resolve charges related to the U.S. Department of Justice's False Declarations Act. However, the spin-offs by these giants are not a contraction, but a refocusing. Undoubtedly, they are divesting non-core, low-growth segments, channeling the resulting cash flow and organizational energy into higher-certainty battlegrounds. Abbott is no exception. After the spin-off, Abbott will focus on its core high-growth, innovation-driven portfolio of medical devices, diagnostics, and established pharmaceuticals. The spun-off nutrition business can also operate as an independent company, allowing for better allocation of strategic resources and a focus on priorities. Looking at Abbott's Q3 results, the spin-off plan has become clearer. In Q3, Abbott achieved revenue of $13.013 billion (+14.5%) and net profit of $920 million, a year-on-year decrease of 44.01%. Within Abbott's business segments, medical devices and established pharmaceuticals are the two main revenue drivers. In Q3, medical device sales grew 6.9% to $5.826 billion. Electrophysiology and cardiac rhythm management saw significant growth, both achieving double-digit increases. However, the nutrition business experienced slower growth and smaller scale compared to other segments, with revenue of $2.262 billion this quarter, representing a year-over-year increase of only 5.1%. At the same time, Abbott lowered its full-year guidance to comparable sales growth of 6.0% and earnings per share of $5.50 to $5.55, down from its previous guidance of sales growth of 6.5% to 7.5% and earnings per share of $5.45 to $5.60. It's worth noting that global medical device giants have frequently spun off their businesses in recent years. Following Medtronic's spin-off of MiniMed and Johnson & Johnson's proposed spin-off of its orthopedic business, DePuy Synthes, Abbott also officially announced the spin-off of its nutrition business into an independent company. Furthermore, business restructuring has been frequently occurring in the past two years. GE Healthcare integrated its imaging business and advanced visualization solutions into the "Advanced Imaging Solutions (AIS)" segment, while simultaneously promoting Patient Care Solutions (PCS) to improve profitability and evaluate its strategic options. Boston Scientific has launched a new round of global restructuring, involving supply chain optimization, production line relocation, and organizational restructuring, which is expected to be largely completed by the end of 2029. Source: https://news.yaozh.com/archive/49226.html

PR Newswire
Oct 23rd, 2026
Abbott's whole-genome Oncodetect test boosts colorectal cancer recurrence detection sensitivity by 30%

Abbott said its whole-genome sequencing Oncodetect test detected colorectal cancer recurrence far more often than the whole-exome version. New Beta-CORRECT data presented at the European Society for Medical Oncology Congress showed a 30-percent absolute improvement in sensitivity within two years of surgery, using a single post-surgery blood draw. The test reached 72.2% sensitivity, against 42.2% for the earlier test. Among 157 patients tested with both, it found circulating tumour DNA (ctDNA) in all 29 patients the older test caught, plus 15 more. Patients with detectable ctDNA after surgery had a 10.6-fold higher risk of recurrence. Two-year disease-free survival was 36.2%, versus 92.3% for ctDNA-negative patients. The study analysed samples from 279 patients, mostly with stage II and III disease. The test tracks up to 5,000 DNA variants unique to each tumour.

Arab Health Media Communication
Oct 23rd, 2026
Mubadala Bio and Abbott collaborate to advance pharmaceutical manufacturing in the UAE.

Mubadala Bio and Abbott collaborate to advance pharmaceutical manufacturing in the UAE. Less than a minute Mubadala Bio and Abbott announced a strategic collaboration during the Abu Dhabi Future Health Summit aimed at supporting local pharmaceutical manufacturing initiatives and contributing to the continued development of the UAE's healthcare ecosystem. The collaboration brings together Mubadala Bio's local manufacturing capabilities and Abbott's longstanding commitment to expanding access to high-quality medicines, with the shared goal of supporting healthcare delivery and advancing pharmaceutical capabilities in the UAE. As part of the collaboration, Abbott and Bioventure Healthcare FZE, a Mubadala Bio company, signed a local manufacturing agreement focused on women's health therapies. The companies are exploring potential future areas of collaboration, including vaccines and biosimilars. Any future collaboration would be subject to further assessment and execution of definitive agreements.

Just Food
Oct 22nd, 2026
India regulator pulls up Nestlé, Abbott over infant-formula violations.

India regulator pulls up Nestlé, Abbott over infant-formula violations. The FSSAI issued a notice to Nestlé India concerning its Lactogen Pro 1 Powder, seeking scientific substantiation for whey protein claims. India's food-safety watchdog has issued notices to the local units of Nestlé and Abbott Laboratories over claims and promotions relating to infant formula. The Food Safety and Standards Authority of India (FSSAI) issued a notice yesterday (21 October) to Nestlé India concerning its Lactogen Pro 1 Powder, seeking scientific substantiation for claims the product "contains whey protein, which is a part of milk protein that is easy to digest". A separate notice concerning Nestlé's NAN Excella Pro Stage 1 questioned the claim that "5 HMOs helps support normal immune system". The regulator said the wording could "imply that the product is suitable for supporting the immune system, suggesting its use in relation to a particular physiological condition". "The claim was considered non-compliant with provisions prohibiting claims relating to the prevention, alleviation, treatment or cure of any disease, disorder or particular physiological condition, unless specifically permitted under applicable regulations," the FSSAI observed. Consequently, Nestlé India was directed to explain why action should not be initiated under the Food Safety and Standards Act 2006, and related rules and regulations. The post featured a "Top 5" list of infant-formula products, including Abbott's Similac Advance 1, Nutricia International's Aptamil Premium 1 and Dexolac 1, Nestlé India's Nan-Pro 1, and Reckitt Benckiser-owned Mead Johnson Nutrition's Enfamil A+ Stage 1. According to the FSSAI, the promotional video breached the Infant Milk Substitutes Act and infant nutrition marketing regulations by attributing benefits such as "balanced nutrition, stronger immunity, brain development and easy digestion to the products". Responding to the notice, Abbott told Just Food it was not involved in the post, had no relationship with the creator, and only became aware of the video after receiving the regulator's notice. "The content was independently created and published by a third party without Abbott's knowledge, involvement or authorisation," the group said, adding that it had communicated the fact to the FSSAI and does not endorse the representations made in the video. The measures form part of a widening FSSAI crackdown on nutritional marketing. In parallel, the regulator issued a so-called show-cause notice to Zydus Wellness Products over claims made on its Complan brand, including "2X Faster Growth", "Supports Concentration and Memory", and "Pro Immunity+ 34 Vital Nutrients". The authority demanded scientific justification for claims that Complan is "clinically proven" to help children grow taller faster, and cited the marketing slogan "Growth Comes in 4 Flavors" as non-compliant with advertising rules. The latest enforcement follows allegations by the regulator that the local arms of Nestlé and Unilever had made "misleading" health claims on adult and maternal nutrition lines. In those cases, Nestlé faced regulatory scrutiny over claims made for its Resource Renal vanilla-flavour powder, marketed for people with chronic kidney disease, while Hindustan Unilever (HUL), the UK-based FMCG group's local listed business, was issued notices on two Horlicks products. Just Food has contacted Mead Johnson Nutrition, Nestlé, Nutricia International, and Zydus Wellness Products in India for comment on the latest notices. Give your business an edge with its leading industry insights.

Telangana Today
Oct 22nd, 2026
FSSAI notices put baby food and nutrition product claims under scrutiny.

FSSAI notices put baby food and nutrition product claims under scrutiny. FSSAI has issued show-cause notices to major food and nutrition companies over claims made for infant formula and children's nutritional drinks. The regulator has sought scientific evidence and explanations, while also questioning the promotion of infant formula products on social media. Published Date - 22 October 2026, 06:10 PM Hyderabad: Wrapping commercial products in scientific-sounding jargon, emotionally playing on parental anxieties to coax them into buying baby food, and pushing unverified health claims to boost sales of health and baby products has, for a long time, been a standard playbook for companies. However, such deceptive and misleading claims are finally being met with resistance, as food regulators and apex courts have started insisting that before flooding the markets with their untested products, MNCs and nutritional giants must prove what they claim in the laboratory first. The recent wave of show-cause notices to Nestle, Abbott, Mead Johnson Nutrition and Zydus, by the Food Safety and Standards Authority of India (FSSAI), against such deceptive advertisements, unverified health claims and promotional violations, has put a spotlight back on the practice of misleading vulnerable consumers and making profit at their cost. The FSSAI action has come in the wake of the Supreme Court's scathing remarks over deceptive advertising and public health safety. The apex court slammed companies that make misleading claims and even hauled up regulators for dragging their feet on clear front-of-pack warning labels, questioning whether undue pressure from powerful food manufacturers has allowed public health interests to be sidelined. The food regulator notices have also made it clear that companies can no longer treat clinical trials as marketing tools. From now on, any claim of enhanced growth due to a product or claims that a specific additive will make a baby's brain grow smarter or better will have to undergo rigorous peer-reviewed scientific scrutiny evaluated directly by regulatory authorities. The authorities have also included social media influencers and digital content creators in regulatory warnings to address a major loophole. In the last few years, such influencers and content creators, through promotional reels and unboxing videos, casually recommend specific baby milk substitutes under the guise of lifestyle advice. Such claims made by influencers are now firmly in the crosshairs of regulatory agencies. Public health specialists familiar with the issue said that FSSAI warnings to big brands over fake health claims on drinks, baby formula, and social media advertisements show that much of the industry relies on guesswork and claims, not on hard facts. Infant Nutrition - Companies rely on scientific jargon, unverified health claims, and parental anxieties to boost sales - Food regulators and the Supreme Court are demanding that nutritional giants prove their claims in the lab before launching products - FSSAI has issued show-cause notices to Nestle, Abbott, Mead Johnson Nutrition, and Zydus over deceptive ads and promotional violations - Companies can no longer use clinical trials as marketing tools - Physical growth and brain-development claims must face rigorous peer-reviewed scrutiny - Regulatory warnings to influencers and content creators who casually push baby milk substitutes under the guise of lifestyle advice - Crackdown exposes an industry built on guesswork and unverified claims rather than hard data * Follow Us: Discover more Try New Foods